Evaluation of interim Dotatate-PET after two cycles of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NET)

被引：0
|
作者：
Duan, H. [1 ]
Song, H. [1 ]
Ferri, V [1 ]
Fisher, G. [1 ]
Shaheen, S. [1 ]
Shah, J. [1 ]
Nguyen, J. [1 ]
Moradi, F. [1 ]
Davidzon, G. [1 ]
Franc, B. [1 ]
Iagaru, A. [1 ]
Mari, Aparici C. [1 ]
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
prrt; net; dotatate; pet; early response; pseudo-progression;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H08
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [1] Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET)
    Duan, H.
    Ferri, V.
    Kunz, P. L.
    Fisher, G. A.
    Moradi, F.
    Davidzon, G. A.
    Franc, B. L.
    Iagaru, A. H.
    Mari, C. Aparici
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S471 - S472
  • [2] Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
    Duan, H.
    Girod, B.
    Ninatti, G.
    Ferri, V
    Kunz, P.
    Fisher, G.
    Moradi, F.
    Davidzon, G.
    Franc, B.
    Lagaru, A.
    Aparici, Mari C.
    NEUROENDOCRINOLOGY, 2020, 110 : 252 - 252
  • [3] Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
    Duan, H.
    Ninatti, G.
    Girod, B.
    Ferri, V
    Guja, K.
    Song, H.
    Kunz, P.
    Fisher, G.
    Lagaru, A.
    Mari, Aparici C.
    NEUROENDOCRINOLOGY, 2020, 110 : 253 - 253
  • [4] Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET)
    Duan, Heying
    Ninatti, Gaia
    Girod, Bradley
    Ferri, Valentina
    Kunz, Pamela L.
    Fisher, George A.
    Moradi, Farshad
    Davidzon, Guido Alejandro
    Franc, Benjamin Lewis
    Iagaru, Andrei
    Mari, Carina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [5] Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
    Duan, H.
    Ferri, V.
    Kunz, P.
    Davidzon, G.
    Nguyen, J.
    Moradi, F.
    Franc, B.
    Iagaru, A.
    Aparici, C. Mari
    PANCREAS, 2021, 50 (03) : 456 - 456
  • [6] FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) after Peptide Receptor Radionuclide Therapy with 177Lu-Dotatate (Lu-PRRT)
    Sansovini, M.
    Stefano, S.
    Ianniello, A.
    Nicolini, S.
    Fantini, L.
    Bongiovanni, A.
    Di Iorio, V
    Sarnelli, A.
    Monti, M.
    Paganelli, G.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 138 - 138
  • [7] Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A two-year single institution experience
    Duan, Heying
    Ninatti, Gaia
    Girod, Bradley
    Ferri, Valentina
    Guja, Kip
    Song, Hong
    Kunz, Pamela
    Fisher, George
    Iagaru, Andrei
    Aparici, Carina Mari
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [8] Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A single institution experience in the USA
    Duan, H.
    Ferri, V.
    Kunz, P. L.
    Fisher, G. A.
    Moradi, F.
    Davidzon, G. A.
    Franc, B. L.
    Iagaru, A. H.
    Mari, C. Aparici
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S468 - S469
  • [9] Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)
    Duan, Heying
    Girod, Bradley
    Ninatti, Gaia
    Ferri, Valentina
    Kunz, Pamela
    Fisher, George
    Moradi, Farshad
    Davidzon, Guido
    Franc, Benjamin
    Iagaru, Andrei
    Aparici, Carina Mari
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [10] Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues
    Bodei, L.
    Pepe, G.
    Paganelli, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2010, 14 (04) : 347 - 351
12345